admin

Admittedly, 2017 so far has kind of been a ho-hum year for former high-flying marijuana stock GW Pharmaceuticals (NASDAQ:GWPH). For the most part, investors have just been waiting for the next big event for the cannabinoid-focused biotech. GW Pharmaceuticals CEO Justin Gover doesn’t think they’ll have to wait much longer. Speaking at the Piper Jaffray […]

by

LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject to market and other conditions, $225 million of American Depositary Shares (“ADSs”) representing ordinary shares […]

by

LONDON, Dec. 06, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 2,400,000 American Depositary Shares (“ADSs”), representing 28,800,000 ordinary […]

by

– Epidiolex® (cannabidiol) NDA Submitted to FDA – – Conference call today at 7:30 a.m. EST –   London, UK, Carlsbad, CA, 4 Dec 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial […]

by

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded higher during Monday’s pre-market session but then sold off after the opening bell. The company’s update on a clinical trial may have been overshadowed by GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s earnings […]

by

LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject to market and other conditions, $225 million of American Depositary Shares (“ADSs”) representing ordinary shares […]

by

Posted 01 November 2017 By Michael Mezher The US Food and Drug Administration (FDA) on Wednesday warned four companies selling cannabidiol (CBD) containing products for making claims that their products can treat or cure cancer and other diseases, including Alzheimer’s, arthritis, heart disease and stroke. “Selling these unapproved products with unsubstantiated therapeutic claims is not […]

by

– Epidiolex® (cannabidiol) NDA Submitted to FDA –– Conference call today at 7:30 a.m. EST – LONDON and CARLSBAD, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial […]

by

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded higher during Monday’s pre-market session but then sold off after the opening bell. The company’s update on a clinical trial may have been overshadowed by GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s earnings […]

by

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded higher during Monday’s pre-market session but then sold off after the opening bell. The company’s update on a clinical trial may have been overshadowed by GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s earnings […]

by

– Epidiolex® (cannabidiol) NDA Submitted to FDA –– Conference call today at 7:30 a.m. EST – LONDON and CARLSBAD, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial […]

by

– Epidiolex® (cannabidiol) NDA Submitted to FDA –– Conference call today at 7:30 a.m. EST – LONDON and CARLSBAD, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial […]

by